FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Almirall, S.A. Stock AnalysisComprehensive stock analysis for Almirall, S.A. (LBTSF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLBTSF
LBTSF
Almirall, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LBTSF
Home🔹Stocks🔹Almirall, S.A.

Almirall, S.A.

LBTSF•OTC

Almirall, S.A.

LBTSF•OTC
Market cap
$3.29B
Sentiment

Your view on LBTSF

Mkt Cap
$3.29B
Sentiment
Your view
LBTSF
Almirall, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LBTSF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Almirall, S.A.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Carlos Gallardo Piqué
Headquarters
Ronda Del General Miter, 151, Barcelona, ES
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Carlos Gallardo Piqué
Headquarters
Ronda Del General Miter, 151, Barcelona, ES
Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News